Acadia Pharmaceuticals | ACAD - Pre Tax Profit


Acadia Pharmaceuticals reported $3.98M in Pre-Tax Profit for its fiscal quarter ending in March of 2026.





Pre Tax Profit Change Date
Acadia Pharmaceuticals USD 3.98M 22.34M Mar/2026
ALKERMES USD -61.93M 122.3M Mar/2026
Alnylam Pharmaceuticals USD 221.65M 60.52M Mar/2026
Biogen USD 377.7M 433.7M Mar/2026
BioMarin Pharmaceutical USD 141.2M 168.36M Mar/2026
Bristol-Myers Squibb USD 1.47B 1.64B Dec/2025
Cara Therapeutics USD -4.91M 3.17M Mar/2025
Corcept Therapeutics USD 9.91M 5.33M Dec/2025
Cytokinetics USD -206.03M 23M Mar/2026
Eisai JPY -7.94B 29.94B Mar/2026
Eli Lilly USD 8.27B 1.03B Dec/2025
Incyte USD 343.6M 46.34M Mar/2026
J&J USD 7.82B 2.86B Mar/2026
Moderna USD -799M 612M Dec/2025
Neurocrine Biosciences USD 246.8M 7.4M Mar/2026
Pfizer USD 5.18B 6.82B Mar/2026
Prothena USD -21.58M 15.33M Dec/2025
PTC Therapeutics USD -2.46M 136.62M Mar/2026
Sarepta Therapeutics USD 343.17M 750.85M Mar/2026
Ultragenyx Pharmaceutical USD -184M 56M Mar/2026
Vanda Pharmaceuticals USD -22.92M 16.68M Dec/2024
Vertex Pharmaceuticals USD 1.25B 78.1M Mar/2026